logo SBA

ETD

Archivio digitale delle tesi discusse presso l’Università di Pisa

Tesi etd-06232023-080138


Tipo di tesi
Tesi di laurea magistrale LM6
Autore
MAGGI, REBECCA
URN
etd-06232023-080138
Titolo
Long-term outcomes of COVID-19 vaccination in patients with rare and complex Connective Tissue Diseases: the ERN-ReCONNET VACCINATE study
Dipartimento
RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
Corso di studi
MEDICINA E CHIRURGIA
Relatori
relatore Prof.ssa Mosca, Marta
tutor Dott.ssa Tani, Chiara
Parole chiave
  • connective tissue diseases
  • covid-19
  • rare diseases
  • vccinations
Data inizio appello
11/07/2023
Consultabilità
Non consultabile
Data di rilascio
11/07/2093
Riassunto
On May 5, 2023, the World Health Organization declared officially the end of the global health emergency caused by SARS-CoV-2; however still today, the virus continues to be present and infect the population, although with a lower risk of developing severe COVID-19 disease than in the past.
This result was achieved thanks to the development of vaccines against SARS-CoV-2. There has been a long debate about their safety and efficacy in the general population and especially in some categories of subjects defined fragile, as they are subjected to a greater risk of infection, hospitalization and death due to the presence of comorbidities and/or due to the intake of immunosuppressive therapies such as in the case of rheumatology patients suffering from rare and complex connective tissue disease (rcCTD).
The European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases has investigated the long-term effects, in terms of efficacy and safety, of anti-COVID-19 vaccinations in patients through the creation of a multicenter observational study with rcCTD.
This study enrolled 363 rcCTD patients (87% female, mean age 51.8 ± 14.6 years) from 9 ERN ReCONNET centers during the period February 2021-October 2021.
Demographic, clinical and vaccination data were acquired for these patients at the time of enrolment. Follow-up visits were subsequently made at 4, 12, 24, 36 and 48 weeks after completion of the first vaccination course. Data on adverse events, disease exacerbations, and the occurrence of new SARS-CoV-2 infections were collected during these visits.
Overall, 200 patients (55.1%) experienced at least one adverse event, generally mild and in most cases occurring immediately after vaccination.
During the follow-up, 55 disease exacerbations were recorded in 39 patients (10.7%), distributed over the entire observation period, although more frequently within 4 weeks of completing the vaccination cycle.
The incidence of new SARS-CoV-2 infections was 8.9 per 1000 person-months, with no cases within 12 weeks of vaccine administration and a trend of increasing infections away from the primary vaccination course.
During the follow-up, 55 disease exacerbations were recorded in 39 patients (10.7%), distributed over the entire observation period, although more frequently within 4 weeks of completing the vaccination cycle.
The incidence of new SARS-CoV-2 infections was 8.9 per 1000 person-months, with no cases within 12 weeks of vaccine administration and a trend of increasing infections away from the primary vaccination course.
Only one case of severe COVID-19 was reported during the study period.
COVID-19 vaccination appears effective and safe in patients with rcCTD.
The rate of new infections was quite low, and serious infections were rare in our cohort.
We have not observed an increased risk of disease exacerbations compared to previous disease history; however, such exacerbations can be potentially serious, underscoring the need for close monitoring of our patients.

File